SE0302546D0 - New compounds - Google Patents
New compoundsInfo
- Publication number
- SE0302546D0 SE0302546D0 SE0302546A SE0302546A SE0302546D0 SE 0302546 D0 SE0302546 D0 SE 0302546D0 SE 0302546 A SE0302546 A SE 0302546A SE 0302546 A SE0302546 A SE 0302546A SE 0302546 D0 SE0302546 D0 SE 0302546D0
- Authority
- SE
- Sweden
- Prior art keywords
- new compounds
- compounds
- therapy
- salts
- processed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0302546A SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | New compounds |
TW093127911A TW200526627A (en) | 2003-09-24 | 2004-09-15 | New compounds |
MXPA06003195A MXPA06003195A (es) | 2003-09-24 | 2004-09-21 | Derivados de 3-heterociclil-indol como inhibidores de glicogeno sintasa cinasa-3 (gsk-3). |
BRPI0414632-8A BRPI0414632A (pt) | 2003-09-24 | 2004-09-21 | composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase 3, de uma doença ou condição, e de distúrbios relacionados aos ossos, processo para a preparação de um composto, e, uso de intermediários |
CA002538381A CA2538381A1 (en) | 2003-09-24 | 2004-09-21 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) |
CNA2004800347007A CN1886397A (zh) | 2003-09-24 | 2004-09-21 | 作为糖原合酶激酶3(gsk3)抑制剂的3-杂环基-吲哚衍生物 |
AU2004273771A AU2004273771B2 (en) | 2002-03-28 | 2004-09-21 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) |
EP04775465A EP1667990A2 (en) | 2003-09-24 | 2004-09-21 | New compounds |
PCT/SE2004/001363 WO2005027823A2 (en) | 2003-09-24 | 2004-09-21 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3) |
UY28528A UY28528A1 (es) | 2003-09-24 | 2004-09-21 | Nuevos compuestos |
US10/572,778 US7683067B2 (en) | 2003-09-24 | 2004-09-21 | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) |
ARP040103394A AR045793A1 (es) | 2003-09-24 | 2004-09-21 | Compuestos derivados de 3-heterociclil-indol |
JP2006527944A JP2007506734A (ja) | 2003-09-24 | 2004-09-21 | 新規な化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0302546A SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | New compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0302546D0 true SE0302546D0 (sv) | 2003-09-24 |
Family
ID=29212538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0302546A SE0302546D0 (sv) | 2002-03-28 | 2003-09-24 | New compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US7683067B2 (xx) |
EP (1) | EP1667990A2 (xx) |
JP (1) | JP2007506734A (xx) |
CN (1) | CN1886397A (xx) |
AR (1) | AR045793A1 (xx) |
AU (1) | AU2004273771B2 (xx) |
BR (1) | BRPI0414632A (xx) |
CA (1) | CA2538381A1 (xx) |
MX (1) | MXPA06003195A (xx) |
SE (1) | SE0302546D0 (xx) |
TW (1) | TW200526627A (xx) |
UY (1) | UY28528A1 (xx) |
WO (1) | WO2005027823A2 (xx) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
SA07280004B1 (ar) * | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
JP2009525325A (ja) * | 2006-02-02 | 2009-07-09 | アストラゼネカ・アクチエボラーグ | 2−ヒドロキシ−3−[5−(モルホリン−4−イルメチル)ピリジン−2−イル]1h−インドール−5−カルボニトリルの遊離塩基又は塩としての医薬用途 |
EP1991539A4 (en) * | 2006-02-28 | 2010-08-25 | Astrazeneca Ab | NEW SALTS OF INDIGENOUS DERIVATIVES AND THEIR USE IN MEDICINE |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007120102A1 (en) * | 2006-04-19 | 2007-10-25 | Astrazeneca Ab | New substituted oxindole derivatives |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
TW201040191A (en) * | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
EP2377850A1 (en) * | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
CN103380125B (zh) | 2010-12-21 | 2015-11-25 | 拜耳知识产权有限责任公司 | 制备三嗪基取代的羟吲哚的方法 |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5940149B2 (ja) * | 1977-11-09 | 1984-09-28 | 大塚製薬株式会社 | オキシインド−ル誘導体 |
US5565580A (en) | 1994-01-27 | 1996-10-15 | Neurosearch A/S | Glutamate Antagonists |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US6569868B2 (en) * | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
EP1183033B1 (en) | 1999-05-21 | 2006-03-01 | Bristol-Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
CA2386218A1 (en) | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
ATE284885T1 (de) | 2000-07-27 | 2005-01-15 | Hoffmann La Roche | 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren |
US20020045566A1 (en) | 2000-10-13 | 2002-04-18 | Gribkoff Valentin K. | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
TW200301123A (en) | 2001-12-21 | 2003-07-01 | Astrazeneca Uk Ltd | New use |
WO2003055877A1 (en) | 2001-12-21 | 2003-07-10 | Astrazeneca Ab | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |
SE0200979D0 (sv) | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
CA2488602A1 (en) * | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
-
2003
- 2003-09-24 SE SE0302546A patent/SE0302546D0/xx unknown
-
2004
- 2004-09-15 TW TW093127911A patent/TW200526627A/zh unknown
- 2004-09-21 AU AU2004273771A patent/AU2004273771B2/en not_active Ceased
- 2004-09-21 UY UY28528A patent/UY28528A1/es not_active Application Discontinuation
- 2004-09-21 CN CNA2004800347007A patent/CN1886397A/zh active Pending
- 2004-09-21 EP EP04775465A patent/EP1667990A2/en not_active Withdrawn
- 2004-09-21 JP JP2006527944A patent/JP2007506734A/ja active Pending
- 2004-09-21 BR BRPI0414632-8A patent/BRPI0414632A/pt not_active IP Right Cessation
- 2004-09-21 AR ARP040103394A patent/AR045793A1/es unknown
- 2004-09-21 WO PCT/SE2004/001363 patent/WO2005027823A2/en active Application Filing
- 2004-09-21 CA CA002538381A patent/CA2538381A1/en not_active Abandoned
- 2004-09-21 US US10/572,778 patent/US7683067B2/en not_active Expired - Fee Related
- 2004-09-21 MX MXPA06003195A patent/MXPA06003195A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06003195A (es) | 2006-06-23 |
US20080275041A1 (en) | 2008-11-06 |
AR045793A1 (es) | 2005-11-16 |
AU2004273771A1 (en) | 2005-03-31 |
WO2005027823A3 (en) | 2005-06-02 |
CA2538381A1 (en) | 2005-03-31 |
TW200526627A (en) | 2005-08-16 |
US7683067B2 (en) | 2010-03-23 |
UY28528A1 (es) | 2005-04-29 |
AU2004273771B2 (en) | 2008-11-06 |
WO2005027823A2 (en) | 2005-03-31 |
CN1886397A (zh) | 2006-12-27 |
EP1667990A2 (en) | 2006-06-14 |
BRPI0414632A (pt) | 2006-11-07 |
JP2007506734A (ja) | 2007-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0301700D0 (sv) | Novel compounds | |
SE0302546D0 (sv) | New compounds | |
SE0200979D0 (sv) | New compounds | |
BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
SE0302811D0 (sv) | Novel compounds | |
SE0101387D0 (sv) | Novel compounds | |
SE0301653D0 (sv) | Novel compounds | |
IS6658A (is) | Ný efnasambönd | |
TW200716529A (en) | New compounds II | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
SE0401971D0 (sv) | Piperidne derivatives | |
EA201000702A1 (ru) | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы | |
MXPA05012247A (es) | Derivados de bencimidazol nuevos. | |
UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
SE0302139D0 (sv) | Novel compounds | |
UY29370A1 (es) | Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones | |
SE0401762D0 (sv) | Novel compounds | |
CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
SV2004001555A (es) | Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos | |
SE0403171D0 (sv) | New compounds | |
SE0303541D0 (sv) | New compounds | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE0301701D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof | |
SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |